Treatment of Blood Cancers - Biopharma Companies Building out their Pipeline of Solutions
Actinium Pharmaceuticals (NYSE: ATNM) has made significant strides in developing its blood cancer treatment pipeline, focusing on Antibody Radiation Conjugates (ARCs) and targeted radiotherapies. Recent highlights include the presentation of preclinical data combining Actimab-A with menin inhibitors at the European Hematology Association (EHA) Congress, and positive Phase 3 SIERRA trial results for Iomab-B in relapsed/refractory AML patients. The SIERRA trial showed a 92% 1-year survival and 69% 2-year survival for patients receiving Iomab-B led bone marrow transplants. Actinium also plans to extend Iomab-B for other blood cancers and introduce Iomab-ACT for enhanced cell and gene therapy outcomes. These advancements are important as biopharma companies work to address the rising incidence of blood cancers globally.
- Actinium's SIERRA trial results show 92% 1-year survival and 69% 2-year survival for Iomab-B treated patients.
- Phase 3 SIERRA trial met its primary endpoint of durable complete remission with Iomab-B.
- Actinium's research on Actimab-A and menin inhibitors presents new therapeutic avenues for AML patients.
- Actinium plans to advance Iomab-B for various blood cancers and develop Iomab-ACT for cell and gene therapy.
- Iomab-B has Orphan Drug Designation from the USFDA and EMA for relapsed/refractory AML in patients 55 and above.
- The SIERRA trial included high-risk patients, highlighting the challenges in treating advanced AML.
- No specific commercial or FDA approval timeline for Actinium's therapies, posing uncertainty for investors.
- Potential for significant competition from other biopharma companies developing AML treatments.
- High dependency on ongoing and future clinical trials for success, which may face delays or failures.
- data on the long-term safety and efficacy of Actinium's therapies, potentially impacting investor confidence.
Insights
Actinium Pharmaceuticals' recent presentations at the 2024 European Hematology Association (EHA) Congress spotlight significant advancements in their targeted radiotherapy treatments for acute myeloid leukemia (AML). The robust Phase 3 SIERRA trial results, showcasing a
Moreover, the combination of Actimab-A with menin inhibitors revumenib and ziftomenib represents an innovative approach to target specific genetic mutations in AML patients, which could pave the way for personalized treatment strategies. The preclinical data validation at EHA adds credence to Actinium's strategy of leveraging ARCs to enhance therapy efficacy.
For retail investors, these findings indicate a promising trajectory for Actinium's pipeline. With ongoing and planned trials aiming to expand Iomab-B's applications and improve outcomes in gene and cell therapies, Actinium showcases a strong commitment to innovation and addressing unmet medical needs in oncology.
From a financial perspective, Actinium's progress in pivotal clinical trials and the promising data presented at major conferences such as the EHA could translate into significant value creation. The Phase 3 SIERRA trial's success may not only bolster Actinium's market position but also attract strategic partnerships or funding opportunities, critical for advancing their pipeline.
Additionally, the Orphan Drug Designation for Iomab-B and Breakthrough Therapy Designation for ziftomenib present regulatory advantages. These designations can expedite development timelines and potentially reduce costs, enhancing the return on investment. The positive clinical outcomes and regulatory support are likely to contribute to market confidence, potentially driving up Actinium's stock price.
Investors should, however, remain cognizant of the high costs and risks associated with clinical-stage biopharmaceuticals. While Actinium's advancements are promising, ongoing trials and regulatory approvals will be important determinants of long-term financial performance.
Actinium Pharmaceuticals operates within a highly competitive and rapidly evolving biopharmaceutical industry. The advancements in their ARCs and targeted radiotherapies align with current market trends focused on personalized medicine and precision oncology. The AML market, characterized by significant unmet needs, presents lucrative opportunities for innovative treatments like Iomab-B and Actimab-A.
The positive trial outcomes and strategic collaborations with entities such as Fred Hutchinson Cancer Research Center enhance Actinium's market credibility. Moreover, the company's proactive engagement in key industry conferences like the EHA and SNMMI highlights their commitment to transparency and stakeholder communication, critical for building investor trust.
However, the competitive landscape includes other biopharma companies also making strides in AML treatment, such as Kura Oncology and Syros Pharmaceuticals. Actinium's ability to differentiate its offerings and demonstrate superior efficacy and safety will be vital for capturing market share.
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 18, 2024) - Investorideas.com, a go-to investing platform covering biotech and medical technology stocks releases the second of a two-part series looking at developments for the treatment of blood cancers, including AML, featuring Actinium Pharmaceuticals, Inc. (NYSE American: ATNM). Actinium is a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies.
Read the full article on Investorideas
https://www.investorideas.com/News/2024/biotech/06180Treatment-of-Blood-Cancers.asp
Approximately every 3 minutes, one person in the US is diagnosed with leukemia, lymphoma or myeloma. Approximately every 9 minutes, someone in the US dies from a blood cancer. This statistic represents approximately 157 people each day or more than six people every hour. This data from the Leukemia and Lymphoma Society demonstrates the growing and urgent demand for solutions.
Behind the scenes and the data, biopharma stocks are developing their unique approaches to treatment and building a pipeline of potential answers.
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) is building out its pipeline and has recently announced progress on several products.
Actinium develops targeted radiotherapies to meaningfully improve survival for people who have failed existing oncology therapies.
"Our Iomab-B and Actimab-A advanced product candidates fill the major unmet medical needs in relapsed or refractory AML in a complementary fashion directed at different parts of the patient journey," they say on their website.
Actinium announced yesterday that an abstract detailing the first ever preclinical data from the combination of menin inhibitors with Actinium's ARC Actimab-A in acute myeloid leukemia (AML) models was presented at the 2024 European Hematology Association (EHA) Congress held June 13 - 16, 2024, in Madrid, Spain. Actinium studied Actimab-A in combination with the leading menin inhibitors, revumenib (Syndax Pharmaceuticals, Inc.) and ziftomenib (Kura Oncology, Inc.), which are being developed for patients with KMT2A rearrangements and NMP1 mutations, which are present in approximately
On June 14th, Actinium announced that results from the Phase 3 SIERRA trial of Iomab-B were presented at the 2024 European Hematology Association (EHA) Hybrid Congress being held June 13 - 16, 2024, in Madrid, Spain. The two presentations at EHA highlighted outcomes in patients with active relapsed or refractory acute myeloid leukemia (r/r AML) enrolled in the SIERRA trial who had a TP53 mutation and long-term efficacy results in this older patient population.
From the news: The Phase 3 SIERRA trial enrolled 153 patients ages 55 and above with active r/r AML and compared outcomes of patients receiving an Iomab-B led bone marrow transplant (BMT) to those of patients receiving physician's choice of care in the control arm. Across all patients in SIERRA study, only patients receiving an Iomab-B led BMT achieved the trial's primary endpoint of durable complete remission with these patients having
Actinium plans to advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes.
On June 11th, Actinium highlighted data from the completed Phase 1b combination trial of Actimab-A + CLAG-M in patients with relapsed or refractory acute myeloid leukemia (r/r AML) at the 2024 Society of Nuclear Medicine & Molecular Imaging (SNMMI) Annual Meeting held June 8 - 11, 2024, in Toronto, Canada. Actimab-A is an ARC comprised of a CD33 targeting monoclonal antibody conjugated with the alpha-particle emitter Actinium-225 isotope payload. Actimab-A has been studied as a single agent and in combination with chemotherapies and targeted therapies in Phase 1 and Phase 2 trials.
In mid-May, Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, announced that it has completed enrollment of 85 patients in the Phase 2 portion of KOMET-001, a registration-directed clinical trial of the Company's menin inhibitor, ziftomenib (KO-539), in patients with relapsed or refractory (R/R) NPM1-mutant acute myeloid leukemia (AML). The Company expects to report topline data from the trial in early 2025.
From the news: "We are thrilled to announce this critical milestone, which brings us one step closer to delivering ziftomenib as a potentially best-in-class treatment for patients with genetically defined acute leukemias," said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology. "Our confidence is supported by our recently announced Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA), which recognizes ziftomenib's potential as an innovative medicine for patients with R/R NPM1-mutant AML and is intended to expedite review as we prepare for submission of a New Drug Application. We are grateful for the KOMET-001 investigators, patients and their families, and we look forward to sharing topline data from this pivotal study early next year."
Continued: Kura announced the first patients dosed in the Phase 2 portion of KOMET-001 in February 2023. The registration-directed study is designed to assess evidence of clinical activity, safety and tolerability of ziftomenib in patients with R/R NPM1-mutant AML, with a primary endpoint of complete response. The study has completed enrollment of the 85 patients necessary to support the primary endpoint analysis.
"The rapid enrollment of this study reflects the urgent need for more effective treatment options in AML as well as the potential for ziftomenib to address this need," said Eunice Wang, M.D., Chief of the Leukemia Service at Roswell Park Comprehensive Cancer Center and principal investigator of the trial. "NPM1-mutant AML represents approximately
Syros Pharmaceuticals (NASDAQ: SYRS) is developing tamibarotene, an oral selective RARα agonist in frontline patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia with RARA gene overexpression.
Syros announced earlier this year that the United States Food and Drug Administration (USFDA) has granted Fast Track Designation to tamibarotene in combination with azacitidine and venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) with RARA overexpression as detected by an FDA approved test in adults who are over age 75 years or who have comorbidities that preclude the use of intensive induction chemotherapy. Tamibarotene, an oral first-in-class selective retinoic acid receptor alpha (RARα) agonist, is currently being evaluated in combination with venetoclax and azacitidine for the treatment of newly diagnosed AML patients with RARA gene overexpression.
"We are pleased to receive Fast Track designation for tamibarotene for the treatment of AML. This designation reflects the tremendous need for a safe and effective therapy, which can improve the clinical outcomes and prognosis among people diagnosed with AML, many of whom cannot tolerate intensive treatment," said David A. Roth, M.D., Chief Medical Officer of Syros Pharmaceuticals. "We are particularly encouraged to secure Fast Track designation following initial randomized data from a prespecified interim analysis of our ongoing SELECT-AML-1 clinical trial, in which treatment with our RARα agonist, tamibarotene, in combination with venetoclax and azacitidine resulted in a
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, announced on June 10th the completion of enrollment as well as positive initial data from the ongoing Phase 2a trial of SLS009, a highly selective CDK9 inhibitor, in relapsed/refractory acute myeloid leukemia (r/r AML).
From the news: "We are pleased to announce the completion of enrollment in the initial portion of our Phase 2a trial representing a significant milestone in the development of SLS009 in AML," said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS. "There has been a high level of enthusiasm from the clinical sites, trial investigators, and patients, reflecting the significant unmet need in the AML patient population previously treated with venetoclax-based regimens. We are extremely grateful to everyone who has helped us achieve this important milestone ahead of schedule."
Continued: Dr. Stergiou continued: "In addition, we are excited to share very promising initial data from this Phase 2a trial. Efficacy was demonstrated across all cohorts far exceeding the targeted ORR of
AML is one of the most common types of leukemia and its incidence is rising globally, including in the Asia-Pacific region, says DataBridgeInsights.
They also reported, "According to a survey by Bristol-Myers Squibb, approximately 1.85 million new cases of blood cancer will be diagnosed worldwide in 2040, with 918,872 cases of lymphoma, 656,345 cases of leukaemia, and 275,047 cases of myeloma. Furthermore, the survey predicted that by 2040, there will be around 1,100,000 fatalities worldwide owing to blood cancer."
Biopharmaceutical stocks like Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) are on the hunt for solutions. Iomab-B was developed at the Fred Hutchinson Cancer Research Center where it was studied in several Phase 1 and Phase 2 trials in almost 300 patients in multiple blood cancer indications, including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin's disease (HD), Non-Hodgkin lymphomas (NHL) and multiple myeloma (MM) and is currently being studied in several ongoing physician trials. Iomab-B has been granted Orphan Drug Designation for relapsed or refractory AML in patients 55 and above by the US Food and Drug Administration (USFDA) and the European Medicines Agency.
Read part one of the series on Investorideas.com
https://www.investorideas.com/news/2024/biotech/06171Biopharma-Stocks.asp
Research biotech and medical device/ tech stocks at Investorideas.com
https://www.investorideas.com/BIS/Stock_List.asp
About Investorideas.com - Big Investing Ideas
Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for sectors including mining, crypto, renewable energy, gaming, biotech, tech, sports and more. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.
Disclaimer/Disclosure: This news article featuring ATNM is a paid for news release creation and dissemination on Investorideas.com. Our site does not make recommendations for purchases or sale of stocks, services or products. This is not investment opinion: Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp. Learn more about publishing your news release and our other news services and prices on the Investorideas.com newswire https://www.investorideas.com/News-Upload/. Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp.
Follow us on X @investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Contact Investorideas.com
800-665-0411
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/213293
FAQ
What recent advancements has Actinium Pharmaceuticals (ATNM) made in blood cancer treatments?
What were the key findings of the Phase 3 SIERRA trial for Actinium's Iomab-B?
What is Actinium Pharmaceuticals' (ATNM) strategy for expanding its treatment pipeline?
What designations has Iomab-B received from regulatory agencies?
What challenges does Actinium Pharmaceuticals (ATNM) face in its clinical trials?
